Your browser doesn't support javascript.
loading
Short-term adverse effects of COVID-19 vaccines after the first, second, and booster doses: a cross-sectional survey from Punjab, Pakistan, and the implications.
Mustafa, Zia Ul; Maqbool, Fareeha; Wahid, Mahnoor; Salman, Muhammad; Haroon, Shahzaib; Khan, Yusra Habib; Mallhi, Tauqeer Hussain; Godman, Brian.
Afiliação
  • Mustafa ZU; Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
  • Maqbool F; Department of Pharmacy Services, District Headquarters Hospital, Pakpattan, Pakistan.
  • Wahid M; Department of Medicine, Faisalabad Medical University, Faisalabad, Pakistan.
  • Salman M; Department of Medicine, Nishtar Medical University, Multan, Pakistan.
  • Haroon S; Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Lahore, Pakistan.
  • Khan YH; Department of Medicine, District Headquarters Hospital, Pakpattan, Pakistan.
  • Mallhi TH; Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
  • Godman B; Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Rev Soc Bras Med Trop ; 56: e0044, 2023.
Article em En | MEDLINE | ID: mdl-37283345
BACKGROUND: Safety and efficacy concerns regarding coronavirus disease 2019 (COVID-19) vaccines are common among the public and have a negative impact on their uptake. We aimed to report the adverse effects currently associated with the vaccine in Pakistan to build confidence among the population for its adoption. METHODS: A cross-sectional study was conducted in five districts of the Punjab province of Pakistan between January and March 2022. The participants were recruited using convenience sampling. All data were analyzed using SPSS 22. RESULTS: We recruited 1622 people with the majority aged between 25-45 years. Of these, 51% were female, including 27 pregnant women and 42 lactating mothers. Most participants had received the Sinopharm (62.6%) or Sinovac (17.8%) vaccines. The incidences of at least one side effect after the first (N = 1622), second (N = 1484), and booster doses (N = 219) of the COVID-19 vaccine were 16.5%, 20.1%, and 32%, respectively. Inflammation/erythema at the injection site, pain at the injection site, fever, and bone/muscle pain were common side effects of vaccination. No significant differences were observed in the adverse effect scores between all demographic variables except for pregnancy (P = 0.012) after the initial dose. No significant association was observed between any variable and the side effect scores of the second and booster doses of the vaccine. CONCLUSIONS: Our study showed a 16-32% prevalence of self-reported side effects after the first, second, and booster COVID-19 vaccinations. Most adverse effects were mild and transient, indicating the safety of different COVID-19 vaccines.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / COVID-19 Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged / Pregnancy País/Região como assunto: Asia Idioma: En Revista: Rev Soc Bras Med Trop Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Malásia País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / COVID-19 Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged / Pregnancy País/Região como assunto: Asia Idioma: En Revista: Rev Soc Bras Med Trop Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Malásia País de publicação: Brasil